Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
2(c) 1.9(c) 1.896(c) 2.035(c) 2.045 Last
194 369 35 952 11 382 47 892 45 300 Volume
-4.31% -5.00% -0.21% +7.33% +0.49% Change
More quotes
Estimated financial data (e)
Sales 2021 15,6 M 17,2 M 17,2 M
Net income 2021 -43,4 M -48,0 M -48,0 M
Net Debt 2021 31,8 M 35,1 M 35,1 M
P/E ratio 2021 -0,53x
Yield 2021 -
Sales 2022 16,1 M 17,8 M 17,8 M
Net income 2022 -11,9 M -13,2 M -13,2 M
Net Debt 2022 56,0 M 61,8 M 61,8 M
P/E ratio 2022 -2,14x
Yield 2022 -
Capitalization 23,6 M 26,1 M 26,1 M
EV / Sales 2021 3,56x
EV / Sales 2022 4,93x
Nbr of Employees 52
Free-Float 81,1%
More Financials
Company
Polyphor AG is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast... 
Sector
Pharmaceuticals
Calendar
09/09Earnings Release
More about the company
Ratings of Polyphor AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about POLYPHOR AG
07/30POLYPHOR : To Layoff 20 Staff After Negative Results From Breast Cancer Treatmen..
MT
07/30EQS-ADHOC : Polyphor to extend period for its strategic evaluation by up to four..
DJ
07/16POLYPHOR : to Halt Study of Breast Cancer Combo, Restructure by Up to 29 Positio..
MT
07/16EQS-ADHOC : Polyphor provides update on the future of the FORTRESS study of bali..
DJ
07/16Polyphor AG Provides Update on the Future of the Fortress Study of Balixafort..
CI
06/28GLOBAL MARKETS LIVE : Volkswagen, Daimler, Tesla, Burberry, UBS...
06/28POLYPHOR : Fails in Late-Stage Breast Cancer Drug Trial; Shares Tank 52%
MT
06/28POLYPHOR : provides update on the Phase III FORTRESS study of balixafortide in p..
EQ
06/28Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in ..
GL
06/28Polyphor AG Provides Update on the Phase III FORTRESS Study of Balixafortide ..
CI
06/08POLYPHOR HOSTING KEY OPINION LEADER : The Need for Novel Therapies for Severe I..
EQ
06/08EQS-ADHOC : Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need..
DJ
06/08POLYPHOR HOSTING KEY OPINION LEADER : The Need for Novel Therapies for Severe I..
GL
06/01POLYPHOR : Balixafortide Shows Antiviral, Anti-Inflammatory Activity Against COV..
MT
06/01POLYPHOR : balixafortide demonstrates consistent dual action anti-viral and anti..
EQ
More news
News in other languages on POLYPHOR AG
07/30Bourse Zurich: le SMI termine avec un nouveau record en séance
07/30Bourse Zurich: le SMI campe dans le rouge
07/30Principales informations en matinée
07/30Bourse Zurich: ouverture en légère baisse
07/30Morning Briefing - Markt Schweiz
More news
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 3
Last Close Price 2,04 CHF
Average target price 7,95 CHF
Spread / Average Target 291%
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-75.03%26
CSL LIMITED3.94%96 600
WUXI BIOLOGICS (CAYMAN) INC.17.80%64 616
SAMSUNG BIOLOGICS CO.,LTD.10.53%51 119
BIOGEN INC.33.44%48 694
ALEXION PHARMACEUTICALS, INC.0.00%40 336